Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: A report from the children's oncology group

Journal of Clinical Oncology

Volumn 26, Issue 14, 2008, Pages 2390-2395

  Aplenc, Richard ^a   Alonzo, Todd A ^b   Gerbing, Robert B ^b   Lange, Beverly J ^b   Hurwitz, Craig A ^b   Wells, Robert J ^b   Bernstein, Irwin ^b   Buckley, Patrick ^b   Krimmel, Kathleen ^b   Smith, Franklin O ^b   Sievers, Eric L ^b   Arceci, Robert J ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; AMINOGLYCOSIDE; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; INFECTION; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; INFANT; MALE; MULTICENTER STUDY; MYELOID LEUKEMIA; PRESCHOOL CHILD; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; MITOXANTRONE; SURVIVAL RATE;

EID: 44249087421     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.0096     Document Type: Article

References (13)

1. Arceci RJ: Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 9:353-360, 2002
2. Sievers EL, Appelbaum FR, Spielberger RT, et al: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678-3684, 1999
3. Sievers EL, Larson RA, Stadtmauer EA, et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001
4. Kell WJ, Burnett AK, Chopra R, et al: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102: 4277-4283, 2003
5. Arceci RJ, Sande J, Lange B, et al: Safety and efficacy of gemtuzumab ozogamicin (Mylotarg(R)) in pediatric patients with advanced CD33-positive acute myeloid leukemia. Blood 106:1183-1188, 2005
6. Zwaan CM, Reinhardt D, Corbacioglu S, et al: Gemtuzumab ozogamicin: First clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 101:3868-3871, 2003
7. McDonald GB, Hinds MS, Fisher LD, et al: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255-267, 1993
8. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
9. Greenwood M: The Natural Duration of Cancer: Reports on Public Health and Medical Subjects (Vol 33, No. 1). London, United Kingdom, HM Stationery Office, 1926, pp 1-26
10. Wells RJ, Adams MT, Alonzo TA, et al: Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group study 2951. J Clin Oncol 21:2940-2947, 2003
11. Milligan DW, Wheatley K, Littlewood T, et al: Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: Results of the MRC AML-HR randomized trial. Blood 107:4614-4622, 2006
12. Lehrnbecher T, Varwig D, Kaiser J, et al: Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 18:72-77, 2004
13. Wadleigh M, Richardson PG, Zahrieh D, et al: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 8:8, 2003